These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9444110)

  • 61. Practical approach to the diagnosis and treatment of anemia associated with CKD in elderly.
    Agarwal AK
    J Am Med Dir Assoc; 2006 Nov; 7(9 Suppl):S7-S12; quiz S17-21. PubMed ID: 17098634
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
    Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
    Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure.
    Locatelli F; Aljama P; Bárány P; Canaud B; Carrera F; Eckardt KU; Hörl WH; Macdougal IC; Macleod A; Wiecek A; Cameron S;
    Nephrol Dial Transplant; 2004 May; 19 Suppl 2():ii1-47. PubMed ID: 15206425
    [No Abstract]   [Full Text] [Related]  

  • 64. Attaining target hemoglobin levels in patients new to dialysis: individualizing therapy based on initial hemoglobin levels.
    Gregory N
    Nephrol Nurs J; 2004; 31(6):672-5. PubMed ID: 15686331
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Categorizing the response to Epoetin alfa therapy. Case study of the anemic patient.
    Watson C
    ANNA J; 1999 Dec; 26(6):629-32. PubMed ID: 10876477
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Monitoring considerations in recombinant human erythropoietin therapy.
    Ogden DA
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):12-5. PubMed ID: 2669080
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Documentation of anemia management interventions. Case study of the anemic patient.
    Kammerer J
    Nephrol Nurs J; 2000 Aug; 27(4):399-402. PubMed ID: 11276631
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparison of the therapeutic efficacy of epoetin beta and epoetin alfa in maintenance phase hemodialysis patients.
    Loughnan A; Ali GR; Abeygunasekara SC
    Ren Fail; 2011; 33(3):373-5. PubMed ID: 21401367
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A successful anaemia management algorithm that achieves and maintains optimum haemoglobin status.
    Benton S
    J Ren Care; 2008 Jun; 34(2):54-8. PubMed ID: 18498568
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The new rHuEPO alpha (epotin) in the management of anemia of end-stage renal disease in patients on maintenance hemodialysis.
    Abbas EE; Afioni N; Al Wakeel J; Bakr MA; Dham R; Donia A; Droubi N; Khidir E; Mathew CM; Mitwali AH; Naga S; Pingle A; Rashed A; Roshdy A; Shaheen F; Shaibani B; Shaibani FM; Shaker DS; Sheiban A; Solieman M
    Transplant Proc; 2004; 36(6):1805-11. PubMed ID: 15350482
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis.
    Jones M; Ibels L; Schenkel B; Zagari M
    Kidney Int; 2004 Mar; 65(3):757-67. PubMed ID: 14871396
    [TBL] [Abstract][Full Text] [Related]  

  • 72. CQI in anemia management: using the fishbone approach to improve outcomes. Case study of the anemic patient.
    Breiterman-White R
    ANNA J; 1999 Apr; 26(2):254-7. PubMed ID: 10418356
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?
    Walker RG
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):935-7. PubMed ID: 18579671
    [No Abstract]   [Full Text] [Related]  

  • 74. Individualizing anaemia treatment: a discussion of case histories.
    Muirhead N
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi37-43. PubMed ID: 15958826
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Case management of the anemic patient. Epoetin alfa: focus on quality of life.
    Butera E
    ANNA J; 1992 Aug; 19(4):410-1. PubMed ID: 1520032
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Implementation of the Anemia Guidelines.
    DeOreo PB; Eschbach JW
    Adv Ren Replace Ther; 1999 Jan; 6(1):18-27. PubMed ID: 9925146
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings.
    Locatelli F; Pisoni RL; Akizawa T; Cruz JM; DeOreo PB; Lameire NH; Held PJ
    Am J Kidney Dis; 2004 Nov; 44(5 Suppl 2):27-33. PubMed ID: 15486871
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Health care outcomes case study: anemia in end-stage renal disease.
    Turco TF
    Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S19-23. PubMed ID: 8846242
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Case study of the anemic patient: epoetin alfa--focus on protocols.
    Kammerer JK
    ANNA J; 1994 Dec; 21(7):440-3. PubMed ID: 7872824
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Managing anemia using laboratory trend analysis. Case study of the anemic patient.
    Aiello J
    ANNA J; 1999 Aug; 26(4):430-3. PubMed ID: 10838975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.